Ensign Peak Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Ensign Peak Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	+1,100	New	+$259K	﹤0.01%	1111
2022 Q4	–	Sell	-10,811	Closed	-$581K	–	2019
2022 Q3	$581K	Hold	10,811	–	–	﹤0.01%	1376
2022 Q2	$602K	Hold	10,811	–	–	﹤0.01%	1365
2022 Q1	$759K	Hold	10,811	–	–	﹤0.01%	1356
2021 Q4	$1.04M	Sell	10,811 -14,250	-57%	-$1.32M	﹤0.01%	1258
2021 Q3	$2.18M	Hold	25,061	–	–	﹤0.01%	1073
2021 Q2	$2.05M	Hold	25,061	–	–	﹤0.01%	1116
2021 Q1	$2.38M	Hold	25,061	–	–	0.01%	1020
2020 Q4	$1.55M	Sell	25,061 -1,924	-7%	-$110K	﹤0.01%	1201
2020 Q3	$1.6M	Sell	26,985 -30,269	-53%	-$2.07M	﹤0.01%	1093
2020 Q2	$4M	Buy	57,254 +30,269	+112%	+$1.92M	0.01%	677
2020 Q1	$1.22M	Hold	26,985	–	–	﹤0.01%	1080
2019 Q4	$1.76M	Buy	+26,985	New	+$1.8M	﹤0.01%	1112

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's LGND Position: Q2 2026 in Review

Ensign Peak Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,100 shares worth $348K. The stake represents ﹤0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in LGND as recently as Q3 2022.

Ensign Peak Advisors first reported a position in LGND in Q4 2019 and has held it in 13 quarters since. The position peaked at $4M in Q2 2020. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Ensign Peak Advisors held 1,100 shares of Ligand Pharmaceuticals worth $348K as of Q2 2026.
Ligand Pharmaceuticals was a new Ensign Peak Advisors position in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1111 holding.
Ensign Peak Advisors first reported a position in Ligand Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
Ensign Peak Advisors's Ligand Pharmaceuticals position peaked at $4M in Q2 2020.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.